Safra Kesesi Kanserleri Tanı ve Tedavi Yaklaşımları

Authors

Mustafa Alçın
https://orcid.org/0009-0002-7193-6546
Mevlüt Harun Ağca

Synopsis

Gallbladder cancer is the most common malignancy of the biliary tract; because it rarely causes symptoms at an early stage, it is usually diagnosed at an advanced stage and carries a poor prognosis. A substantial proportion of cases are detected incidentally after cholecystectomy performed for symptomatic gallstones. Gallstone-related chronic inflammation, porcelain gallbladder, polypoid lesions, pancreaticobiliary maljunction and geographic/ethnic factors are the main risk factors. Contrast-enhanced cross-sectional imaging is the mainstay of diagnosis and staging, and staging laparoscopy can detect peritoneal and superficial liver metastases missed by imaging. Surgical resection is the only potentially curative treatment; the extent of surgery is determined by T stage, and radical re-resection including liver resection and lymphadenectomy is recommended for incidental ≥T1b disease. After resection, 5-fluorouracil-based adjuvant chemotherapy with capecitabine or S-1 is the recommended approach. In advanced disease, the addition of durvalumab or pembrolizumab to gemcitabine–cisplatin is the standard first-line treatment, and molecular profiling is recommended to identify targetable alterations. This chapter summarizes the epidemiology, risk factors, pathology, diagnosis and staging, and surgical and systemic treatment of gallbladder cancer in light of current guidelines and high-level evidence.

References

Roa JC, García P, Kapoor VK, et al. Gallbladder cancer. Nature Reviews Disease Primers. 2022;8(1): 69. doi:10.1038/s41572-022-00398-y

Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. The Lancet. 2021;397(10272): 428–444. doi:10.1016/S0140-6736(21)00153-7

Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clinical Epidemiology. 2014;6: 99–109. doi:10.2147/CLEP.S37357

Ramamoorthy T, Kulothungan V, Vijayakumar S, et al. Risk factors and clinical predictors associated with incidental gallbladder cancer: a systematic review and meta-analysis. Journal of Gastrointestinal Cancer. 2025;56(1): 247. doi:10.1007/s12029-025-01369-8

Chen LT, Vogel A, Hsu C, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. ESMO Open. 2024;9(8): 103647. doi:10.1016/j.esmoop.2024.103647

Schnelldorfer T. Porcelain gallbladder: a benign process or concern for malignancy? Journal of Gastrointestinal Surgery. 2013;17(6): 1161–1168. doi:10.1007/s11605-013-2170-0

Foley KG, Riddell Z, Coles B, et al. Risk of developing gallbladder cancer in patients with gallbladder polyps detected on transabdominal ultrasound: a systematic review and meta-analysis. The British Journal of Radiology. 2022;95(1137): 20220152. doi:10.1259/bjr.20220152

Foley KG, Lahaye MJ, Thoeni RF, et al. Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE. European Radiology. 2022;32(5): 3358–3368. doi:10.1007/s00330-021-08384-w

Aloia TA, Járufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB. 2015;17(8): 681–690. doi:10.1111/hpb.12444

Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2): 182–188. doi:10.1111/his.13975

Arends MJ, Esposito I, Gill AJ, et al. Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system. Histopathology. 2026;88(7): 1295–1314. doi:10.1111/his.70116

Vogel A, Ducreux M, ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1): 104003. doi:10.1016/j.esmoop.2024.104003

Zhu Y, Wu JA, Zhang D, et al. Global patterns of mutational profiles in biliary tract cancer. Journal of Hepatology. 2026;85(2): 271–288. doi:10.1016/j.jhep.2026.03.029

Parida GK, Panda RA, Agrawal K. Impact of fluorine-18-fluorodeoxyglucose PET/computed tomography in staging of patients with gallbladder cancer: a systematic review and meta-analysis. Nuclear Medicine Communications. 2021;42(8): 846–854. doi:10.1097/MNM.0000000000001405

Agarwal AK, Kalayarasan R, Javed A, et al. The role of staging laparoscopy in primary gall bladder cancer—an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Annals of Surgery. 2013;258(2): 318–323. doi:10.1097/SLA.0b013e318271497e

Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Annals of Surgical Oncology. 2018;25(4): 845–847. doi:10.1245/s10434-017-6025-x

Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Annals of Surgery. 2015;261(4): 733–739. doi:10.1097/SLA.0000000000000728

Søreide K, Guest RV, Harrison EM, et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy. The British Journal of Surgery. 2019;106(1): 32–45. doi:10.1002/bjs.11035

Lee SE, Jang JY, Lim CS, et al. Systematic review on the surgical treatment for T1 gallbladder cancer. World Journal of Gastroenterology. 2011;17(2): 174–180. doi:10.3748/wjg.v17.i2.174

Lee H, Kwon W, Han Y, et al. Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis. Journal of Hepato-Biliary-Pancreatic Sciences. 2018;25(2): 131–141. doi:10.1002/jhbp.521

Widmann B, Warschkow R, Beutner U, et al. Effect of lymphadenectomy in curative gallbladder cancer treatment: a systematic review and meta-analysis. Langenbeck's Archives of Surgery. 2020;405(5): 573–584. doi:10.1007/s00423-020-01878-z

Pandey M, Chakraborty S, Hansalia D, et al. Defining surgical excellence in gallbladder cancer: a meta-analysis validating the 6-node threshold and extended D2 lymphadenectomy across all T-stages. European Journal of Surgical Oncology. 2026;52(6): 111804. doi:10.1016/j.ejso.2026.111804

Han HS, Yoon YS, Agarwal AK, et al. Laparoscopic surgery for gallbladder cancer: an expert consensus statement. Digestive Surgery. 2019;36(1): 1–6. doi:10.1159/000486207

Li D, Xu L, Deng X, et al. Laparoscopic versus open surgery in treating patients with gallbladder cancer: a systematic review and meta-analysis. Hepatobiliary Surgery and Nutrition. 2024;13(3): 444–459. doi:10.21037/hbsn-22-597

Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. Journal of Gastrointestinal Surgery. 2007;11(11): 1478–1486. doi:10.1007/s11605-007-0309-6

Ethun CG, Postlewait LM, Le N, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. JAMA Surgery. 2017;152(2): 143–149. doi:10.1001/jamasurg.2016.3642

Selvakumar B, Patkar S, Nekarakanti PK, et al. Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis. HPB. 2026;28(3): 255–265. doi:10.1016/j.hpb.2025.12.017

Loke S, Low CE, Ong BDC, et al. Efficacy of neoadjuvant therapy in gallbladder cancer: a meta-analysis using reconstructed time-to-event data. Journal of Gastrointestinal Surgery. 2025;29(9): 102133. doi:10.1016/j.gassur.2025.102133

Engineer R, Patkar S, Lewis SC, et al. A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol. BMJ Open. 2019;9(6): e028147. doi:10.1136/bmjopen-2018-028147

Goetze TO, Bechstein WO, Bankstahl US, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR) - the AIO/CALGP/ACO-GAIN-trial. BMC Cancer. 2020;20(1): 122. doi:10.1186/s12885-020-6610-4

Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5): 663–673. doi:10.1016/S1470-2045(18)30915-X

Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. Journal of Clinical Oncology. 2022;40(18): 2048–2057. doi:10.1200/JCO.21.02568

Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. 2023;401(10372): 195–203. doi:10.1016/S0140-6736(22)02038-4

Edeline J, Hirano S, Bertaut A, et al. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. European Journal of Cancer. 2022;164: 80–87. doi:10.1016/j.ejca.2022.01.009

Akkus E, Lamarca A. Adjuvant chemotherapy compared to observation in resected biliary tract cancers: survival meta-analysis of phase-III randomized controlled trials. European Journal of Cancer. 2025;220: 115342. doi:10.1016/j.ejca.2025.115342

Benson AB, D'Angelica MI, Abrams T, et al. Biliary tract cancers, version 2.2025, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2025;23(9): 403–418. doi:10.6004/jnccn.2025.0042

Zeng D, Wang Y, Wen N, et al. Impact of adjuvant therapy on survival outcomes in resected gallbladder cancer: a systematic review and meta-analysis. Hepatobiliary Surgery and Nutrition. 2026;15(2): 36. doi:10.21037/hbsn-24-433

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England Journal of Medicine. 2010;362(14): 1273–1281. doi:10.1056/NEJMoa0908721

Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8): EVIDoa2200015. doi:10.1056/EVIDoa2200015

Oh DY, He AR, Qin S, et al. Durvalumab plus chemotherapy for advanced biliary tract cancer: a post hoc analysis of the TOPAZ-1 randomized clinical trial. JAMA Oncology. 2026;12(9): 960–964. doi:10.1001/jamaoncol.2026.2204

Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;401(10391): 1853–1865. doi:10.1016/S0140-6736(23)00727-4

Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology. 2021;22(5): 690–701. doi:10.1016/S1470-2045(21)00027-9

Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. Journal of Clinical Oncology. 2015;33(24): 2617–2622. doi:10.1200/JCO.2014.60.2219

Choi SH, Rim CH, Shin IS, et al. Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis. Hepatology International. 2022;16(3): 712–727. doi:10.1007/s12072-022-10343-6

Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet Oncology. 2023;24(7): 772–782. doi:10.1016/S1470-2045(23)00242-5

Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. Journal of Clinical Oncology. 2024;42(1): 47–58. doi:10.1200/JCO.23.02005

Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. The Lancet Oncology. 2020;21(9): 1234–1243. doi:10.1016/S1470-2045(20)30321-1

Marabelle A, O'Malley DM, Hendifar AE, et al. Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer. 2025;6(2): 253–258. doi:10.1038/s43018-024-00894-y

Published

November 16, 2026

License

License